3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China
Home-Grown Partnership Pays Dividends
Executive Summary
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
You may also be interested in...
China’s CDE Explains Major Issues Around Conditional Approval Scheme
China's conditional approval system, which is an accelerated pathway, is being increasingly used by pharma firms, but some thorny issues remain such as the impact on full approvals, the scheme’s relation to priority reviews and currently available therapies and deadlines for confirmatory studies. Staff from the country's Center for Drug Evaluation discussed various topics around the system in a recent article.
Great Leap: Major Chinese Pharmas See Innovative Drug Sales Breakthrough in H1
A number of major Chinese pharma firms, including Simcere and Hansoh, brought in more revenues from innovative drugs than generics in the first half, a major stand-out from their domestic peers.
AZ, Junshi Part Ways Amid China IO Commercial Struggle
Multinationals including AstraZeneca are retreating from China’s overcrowded immuno-oncology market but one exception - Pfizer - remains steadfast.